Dicerna (DRNA) announced the closing of the global licensing and research collaboration between Dicerna and Eli Lilly (LLY) following clearance under the HSR Act. The companies entered into a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain. The companies will utilize Dicerna’s proprietary GalXC RNAi technology platform to progress new drug targets toward clinical development and commercialization. In addition, the partners will collaborate to move beyond the current technical paradigm in order to generate next-generation oligonucleotide therapeutic agents. Dicerna will receive an upfront payment of $100M, as well as an equity investment of $100M at a premium. Dicerna is also eligible to receive up to approximately $350M per target in development and commercialization milestones, as well as tiered royalties ranging from the mid-single to low-double digits on product sales. The two companies anticipate collaborating on more than 10 targets.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.